Subjects undergoing elective major orthopedic surgery (expected bleeding greater than 500 ml)
Conditions
Interventions
Roxarestat group:100mg oral roxarestat given 3 times weekly for 3 weeks preoperatively
Sponsors
The second affiliated hospital of Zhejiang University school of medicine
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. age >= 18 years and gender; 2. subjects undergoing elective major orthopedic surgery (expected bleeding >500 ml); 3. subjects with anemia (hemoglobin level: <130g/L for men, <120g/L for women); 4. agree to participate in this trial and voluntarily sign the informed consent form;
Exclusion criteria
Exclusion criteria: 1. Emergency admissions; 2. Patients with tumors; 3. Patients with more than moderate anemia (<90g/L); 4. Patients already enrolled in other clinical studies; 5. Patients who are unable to follow the study plan due to cognitive function, language impairment, etc. 6. Pregnant or breastfeeding patients; 7. Patients who have been treated with erythropoietic drugs, iron or other hemoglobin-raising therapy; 8. Patients with severe infections; 9. Patients with acute coronary syndromes, cardiac insufficiency and cerebrovascular events within 3 months; 10. Any other medical condition that may pose a safety risk to the study participants, confound the efficacy or safety assessment, or interfere with participation in the study will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of compound outcomes of perioperative transfusion requirements; | — |
Countries
China
Contacts
Public ContactMin Yan
The second affiliated hospital of Zhejiang University school of medicine
Outcome results
None listed